Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
13. juni 2018 oppdatert av: Seong-Gyu Ko, Kyunghee University Medical Center
A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Euiiyin-tang on Obese Patients
The hypothesis of this study is obese patient with Euiiyin-tang for 12 weeks will show a superior reduction compared to those taking the placebo.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study has two arms, Euiiyin-tang and placebo group.
Inclusion of 80 patient each arm.
They will be screened at first visit.
At the baseline, that is the second visit, they will be evaluated each outcomes including weight, waist circumference, lipid profile (total cholesterol, triglyceride), CRP (C-reactive protein), visceral fat area and subcutaneous fat area using abdominal computed tomography (CT), questionnaires of QoL (Quality of Life) and eating attitudes, etc.
The Euiiyin-tang will provide to the patients from the baseline, it contains 4 weeks of serving.
After 4 weeks, the visit 3, the evaluation procedure will be repeated except lipid profile, CRP, abdominal CT.
Another Euiiyin-tang of 4 weeks will be given to the patient.
The visit 4, 4 weeks after the visit 3, the same procedure will be repeated.
The visit 5, 12 weeks after from the baseline, the patient will be evaluated including weight, waist circumference, lipid profile, CRP, visceral fat area and subcutaneous fat area using abdominal computed tomography, questionnaires of QoL and eating attitudes, etc.
Studietype
Intervensjonell
Registrering (Faktiske)
149
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Incheon, Korea, Republikken, 405-760
- Gachon University Gil Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Women aged 18-65 years old
- Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose < 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening
- Agreed to low-calorie diet during the trial
- Written informed consent of the trial
Exclusion Criteria:
- Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.
- Heart disease (heart failure, angina pectoris, myocardial infarction)
- Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
- Malignant tumour or lung disease
- Cholelithiasis
- Severe renal disability (SCr > 2.0 mg/dL)
- Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
- Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over
- Narrow angle glaucoma
- History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
- History of stroke or temporary ischemic cardioplegia
- History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
- Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)
- Use of β--blocker or diuretic as hypertension medication within last 3 months
- Use of medication for central nervous system or central active weight reduction medication
- Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
- Difficult to measure anthropometric dimensions because of anatomical change such as resection
- Surgical history for weight reduction; bariatric surgery, etc.
- Unable to follow instructions of the trial as judged by investigator
- Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2 years of menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, etc.)
- Use of other investigational product within last 1 month
- Reduction over 10% of the previous weight within 6 months
- Decided to stop smoking within last 3 months; however, keeping irregular smoking habit
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Euiiyin-tang
powder type, 3 times per day before the meal, 12 weeks total
|
Korean medicinal herbal drug
|
|
Placebo komparator: Placebo
powder type, 3 times per day before the meal, 12 weeks total
|
Placebo drug, same odor and formula as Euiiyin-tang
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Weight reduction
Tidsramme: between baseline and 12 weeks
|
between baseline and 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
C-reactive protein (CRP)
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Blood pressure
Tidsramme: baseline, 4 weeks, 8 weeks, and 12 weeks
|
baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
|
Blood glucose
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Waist/hip ratio
Tidsramme: 4 weeks, 8 weeks, and 12 weeks
|
4 weeks, 8 weeks, and 12 weeks
|
|
|
Waist circumference
Tidsramme: baseline, 4 weeks, 8 weeks, and 12 weeks
|
baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
|
Korean Obesity-related Quality of Life scale
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Korean version of Eating Attitudes Test-26
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Total cholesterol
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Triglyceride
Tidsramme: baseline and 12 weeks
|
baseline and 12 weeks
|
|
|
Visceral fat area
Tidsramme: baseline and 12 weeks
|
Using abdominal computed tomography
|
baseline and 12 weeks
|
|
Subcutaneous fat area
Tidsramme: baseline and 12 weeks
|
Using abdominal computed tomography
|
baseline and 12 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Yoon-kyung SONG, KMD, Gachon University Medical Center
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Cheon C, Song YK, Ko SG. Efficacy and safety of Euiiyin-tang in Korean women with obesity: A randomized, double-blind, placebo-controlled, multicenter trial. Complement Ther Med. 2020 Jun;51:102423. doi: 10.1016/j.ctim.2020.102423. Epub 2020 May 21.
- Cheon C, Jang S, Park JS, Ko Y, Kim DS, Lee BH, Song HJ, Song YK, Jang BH, Shin YC, Ko SG. Euiiyin-tang in the treatment of obesity: study protocol for a randomised controlled trial. Trials. 2017 Jun 21;18(1):289. doi: 10.1186/s13063-017-2039-8.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. april 2013
Primær fullføring (Faktiske)
1. februar 2015
Studiet fullført (Faktiske)
1. juni 2017
Datoer for studieregistrering
Først innsendt
2. november 2012
Først innsendt som oppfylte QC-kriteriene
8. november 2012
Først lagt ut (Anslag)
9. november 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. juni 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. juni 2018
Sist bekreftet
1. juni 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HP001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .